EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, PuraPharm's enterprise value is HK$701.6 Mil.
PuraPharm's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$406.9 Mil. Therefore, PuraPharm's EV-to-Revenue for today is 1.72.
The historical rank and industry rank for PuraPharm's EV-to-Revenue or its related term are showing as below:
HKSE:01498'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.38 Med: 1.3 Max: 2.1
Current: 1.72
During the past 10 years, the highest EV-to-Revenue of PuraPharm was 2.10. The lowest was 0.38. And the median was 1.30.
HKSE:01498's EV-to-Revenue is ranked better than 62.22% of 1027
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs HKSE:01498: 1.72
As of today (2024-04-26), PuraPharm's stock price is HK$0.75.
PuraPharm's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.03. Therefore, PuraPharm's PS Ratio for today is 0.73.
PuraPharm EV-to-Revenue Historical Data
The historical data trend for PuraPharm's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PuraPharm's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PuraPharm's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PuraPharm's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where PuraPharm's EV-to-Revenue falls into.
PuraPharm's current Enterprise Value is HK$701.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PuraPharm's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$406.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PuraPharm's share price for today is HK$0.75.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PuraPharm EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of PuraPharm's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. In addition, the organization is engaged in rendering Chinese medical diagnostic services. The operating segments of the group are China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation and Clinics. It generates maximum revenue from the China CCMG segment mainly engages in the production and sale of CCMG products in China. The group derives revenue from the customers located in Hong Kong, Mainland China and Other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01498 has been successfully added to your 